Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
Authors
Keywords
Melanomas, Adverse events, Cancer treatment, Database searching, Meta-analysis, Vomiting, Nausea, Neutropenia
Journal
PLoS One
Volume 9, Issue 12, Pages e111920
Publisher
Public Library of Science (PLoS)
Online
2014-12-12
DOI
10.1371/journal.pone.0111920
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
- (2013) B Sherrill et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions
- (2013) Jack Murrell et al. CANCER TREATMENT REVIEWS
- Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
- (2013) Caroline Robert et al. LANCET ONCOLOGY
- A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
- (2013) Chuanliang Cui et al. MOLECULAR THERAPY
- Management of Primary Cutaneous and Metastatic Melanoma
- (2013) Krista M. Rubin Seminars in Oncology Nursing
- A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy
- (2011) Guan Jiang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma
- (2011) S O'Day et al. BRITISH JOURNAL OF CANCER
- Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sezary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins
- (2011) C. Querfeld et al. CLINICAL CANCER RESEARCH
- A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole
- (2011) ZhiQiang Yin et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Evolution of Melanoma Diagnosis: 25 Years Beyond the ABCDs
- (2010) D. S. Rigel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy
- (2010) Richard Kefford et al. Molecular Cancer
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group
- (2008) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started